Right now your agent behaves like a generic “drug info bot”, but your track is “digital medical rep for HCPs”, which is a richer and more constrained persona. The fix is less about more drugs and more about sharpening *who* it serves, *what* it’s allowed to do, and *how* it responds.

## Why the current answer feels weak

Your answer:

> “I’m designed to provide information about specific drugs in our database… you can ask me about any of our 31 drugs…”

Two issues:

* It breaks the illusion of a **medical rep** and sounds like a toy demo.
* It exposes internal limitations (“31 drugs”) instead of pivoting the conversation into something clinically useful.

Also, your track is explicitly  *HCP‑facing* , not patient self‑service, and regulators expect HCP chatbots to stick to approved content and avoid diagnosis or treatment recommendations based purely on symptoms.[healthcareadvertising.gobfw**+1**](https://healthcareadvertising.gobfw.com/ai-pharma-chatbots-medical-information-access/)

So saying “I can’t diagnose or prescribe, but here’s how I can support you as a clinician” is correct – but you need to say it in a smarter way.

## How to make it feel like a real “digital rep”

Think of your agent as a virtual Med Info / brand rep:

1. **Declare the persona up front**

   * “I’m a digital medical representative for common primary‑care drugs in India. I help licensed HCPs with evidence‑based information, not direct patient prescriptions.”
   * On the UI, add a small banner: “For healthcare professionals only. Not for self‑medication.”
2. **Structure its capabilities around HCP workflows**
   For any in‑scope drug, your answers should routinely cover:

   * **Scientific** : MoA, key trials, efficacy vs comparators, dosing (incl. renal/hepatic adjustments), key contraindications.[digitalya**+1**](https://digitalya.co/blog/using-genai-chatbots-for-hcp-portals/)
   * **Administrative** : PM‑JAY / CGHS / ESIC / private coverage summary, Jan Aushadhi option + price, OPD vs IP coverage.[[ppl-ai-file-upload.s3.amazonaws](https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/50564800/38884de1-4bf6-4a43-94c5-a3033c1c4e73/reimbursement.json)]
   * **Positioning vs competitors** : Use `comparisons.json` to answer “How does this differ from X?” (e.g., Atorvastatin vs Rosuvastatin, Amlodipine vs ARBs).[[ppl-ai-file-upload.s3.amazonaws](https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/50564800/62c18064-b9c8-4af2-99a9-5da152602f59/comparisons.json)]
   * **Interactions and safety flags** : Use `interactions.json` to surface critical “don’t combine” or “use with caution” messages in a med‑rep tone.[[ppl-ai-file-upload.s3.amazonaws](https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/50564800/3fca57e6-185c-44ae-8a4c-8bd99e2daa2c/interactions.json)]

   So instead of “Tell me about Paracetamol”, the rep can offer a short detailing card:

   * “Paracetamol – MoA, dose ranges, key safety, Jan Aushadhi price, scheme coverage, and where it fits vs ibuprofen/diclofenac.”
3. **Make the “31 drugs” limitation invisible**

   * Never say “I only know 31 drugs.”
   * Instead: “I currently support a curated set of high‑volume primary care molecules. If your question is about a different product, I can’t yet provide reliable information on it.”

   If you later plug in OpenFDA / CDSCO / labels, you can quietly expand coverage without changing the UX.

## Handling symptom‑style questions without looking dumb

You’re right: simply refusing looks bad. But giving consumer‑level treatment advice is risky and goes against emerging guidance (studies show general chatbots often give incorrect or even harmful drug advice when used by patients).[pubmed.ncbi.nlm.nih**+1**](https://pubmed.ncbi.nlm.nih.gov/37263772/)

You can do a **two‑step, persona‑aware response** instead.

1. **Detect that the query is symptom‑based and ambiguous**

   * “I have fever and dry cold, what medicine should I take?” → “symptom question, likely patient”.
2. **Respond like this (template)**
   Something along these lines:

   > “This assistant is intended for healthcare professionals and cannot diagnose or prescribe based only on symptoms.
   >
   > If you’re a patient, please see a doctor for a proper examination – self‑medicating, even with common drugs like paracetamol or antibiotics, can be unsafe.
   >
   > If you’re an HCP asking on behalf of a patient, tell me the working diagnosis (for example ‘uncomplicated viral URTI in adult, no comorbidities’) and which drug you’re considering. I can then help with labeled information, dosing ranges, safety considerations, interactions, and reimbursement under PM‑JAY / CGHS / ESIC.”
   >

   That way:

   * You stay compliant (no direct OTC recommendation).[pmc.ncbi.nlm.nih**+1**](https://pmc.ncbi.nlm.nih.gov/articles/PMC10097741/)
   * You guide HCPs into an *appropriate* use of the tool (drug‑specific, evidence‑based Q&A).

You can also,  *purely educationally* , add one sentence like:

> “In general, doctors often use paracetamol to relieve fever, but the right dose and suitability depend on age, liver function, pregnancy status, and other medicines the patient is taking.”

This gives value without saying “you should take X”.

## Deep research & datasets you can add to make it richer

Right now your JSONs are already unusually strong: they encode drugs, scheme coverage, interactions, and comparisons.[drugs_master.json**+3**](https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/50564800/e1348719-f39e-4bba-8d2c-45003ebb47ec/drugs_master.json)

To level up from “chatbot” to “serious digital rep”, you can layer in *more authoritative sources* and specific HCP‑style content:

1. **Regulatory labels and MI principles**

   * Pull structured content from **official product labels / prescribing information** (FDA, EMA, CDSCO, VMS/CGHS/MSO PDFs you already have), and clearly mark answers as “from label”.[healthcareadvertising.gobfw**+1**](https://healthcareadvertising.gobfw.com/ai-pharma-chatbots-medical-information-access/)
   * Follow existing principles for digital medical information: non‑promotional, evidence‑based, label‑adherent, and clearly separating *on‑label* info from anything else.[[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC10097741/)]
2. **Clinical guidelines and trial summaries**
   For your 31 drugs, map to:

   * Key international or Indian guidelines (AHA/ESC for statins and ARBs, ADA for metformin, GINA for budesonide/salbutamol, WHO typhoid guidance for azithro/ceftriaxone, etc.).[octopi**+1**](https://www.octopi.blog/cpi/10-use-cases-for-ai-in-pharma)
   * 1–2 pivotal trials or landmark studies per major comparison (URANUS for statins, ONTARGET for ARBs, UKPDS for metformin, etc. – some already referenced in `comparisons.json`).[[ppl-ai-file-upload.s3.amazonaws](https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/50564800/62c18064-b9c8-4af2-99a9-5da152602f59/comparisons.json)]

   Then add a “Evidence & guidelines” section in answers:

   * “Guidelines: ADA 2024 recommends metformin as first‑line for most T2DM…”
   * “Key trial: UKPDS showed long‑term CV benefit…”
3. **More administrative richness**
   You already have good government‑scheme coverage.[[ppl-ai-file-upload.s3.amazonaws](https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/50564800/38884de1-4bf6-4a43-94c5-a3033c1c4e73/reimbursement.json)]

   You could deepen:

   * Simple **private insurance archetypes** (generic “typical retail IP policy” rules: IP vs OPD drug coverage, pre‑existing waiting period).[[healthcareadvertising.gobfw](https://healthcareadvertising.gobfw.com/ai-pharma-chatbots-medical-information-access/)]
   * A few **country‑specific payer examples** if you want global flavour later, but that might be overkill now.
4. **“Rep‑style” FAQs and objection handling**
   For each drug, pre‑write 3–5 FAQs an HCP might ask a rep, like:

   * “How does this differ from [main competitor]?”
   * “Is it safe in CKD stage 3?”
   * “Any special considerations in pregnancy?”
   * “What happens if I combine this with X (common interaction)?”

   These can pull from your existing `comparisons.json` and `interactions.json`, but framed in natural language.[interactions.json**+1**](https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/50564800/3fca57e6-185c-44ae-8a4c-8bd99e2daa2c/interactions.json)[[healthcareadvertising.gobfw](https://healthcareadvertising.gobfw.com/ai-pharma-chatbots-medical-information-access/)]
5. **Safety alerts / updates**

   * Maintain a small JSON of  **recent safety alerts** , black‑box warnings, or recalls relevant to your molecules (e.g., NSAID CV risk, azithromycin QT issues, metformin + contrast).[pubmed.ncbi.nlm.nih**+1**](https://pubmed.ncbi.nlm.nih.gov/37263772/)
   * Let the rep proactively surface: “Important: azithromycin can prolong QT; use caution with statins and other QT‑prolonging drugs.”

## Concrete feature ideas to de‑“chatbotify” it

Here are some implementable features that make the experience feel like a digital rep rather than a toy:

1. **Mode classification**
   On each query, classify into:

   * Clinical scientific (MoA, dosing, efficacy, safety).
   * Administrative (coverage, pricing, Jan Aushadhi, schemes).
   * Patient‑style / symptom‑based.
   * Out‑of‑scope.

   Then route to different answer templates and guardrails.
2. **Detailing cards and follow‑ups**
   When an HCP asks “Tell me about Atorvastatin”, you answer with:

   * Short structured card (MoA, dose, key benefit vs rosuvastatin, safety highlights, coverage summary).[reimbursement.json**+1**](https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/50564800/38884de1-4bf6-4a43-94c5-a3033c1c4e73/reimbursement.json)
   * Then offer smart follow‑ups:
     * “Do you want to see comparison vs Rosuvastatin?”
     * “Do you want CGHS/ESIC coverage details?”
     * “Any specific patient scenario (e.g., CKD, diabetes)?”
3. **Scenario‑based support for HCPs**
   Instead of patients asking “I have fever…”, encourage prompts like:

   * “Adult with viral fever, on metformin and losartan – is ibuprofen ok?”
   * The agent can then check interactions and suggest safer alternatives in an HCP tone (e.g., prefer paracetamol, monitor renal function), explicitly framed as  *information* , not orders.[[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC10097741/)][[ppl-ai-file-upload.s3.amazonaws](https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/50564800/3fca57e6-185c-44ae-8a4c-8bd99e2daa2c/interactions.json)]
4. **Personalised for specialty (if you have time)**
   If you have a simple profile toggle:

   * “I’m a cardiologist / diabetologist / GP” → you bias follow‑ups and examples to that specialty (statins, ARBs, metformin, etc.).[digitalya**+1**](https://digitalya.co/blog/hcp-engagement-ai-pharma/)

---

If you want, next step I can help you rewrite your *system prompt + answer templates* so that even with the same 31‑drug JSONs, the agent:

* Sounds like a compliant digital med rep.
* Handles symptom‑style questions gracefully.
* Surfaces scientific + administrative info in a way that impresses HCP judges instead of feeling like “just a chatbot”.
